Schedule of Selected Quarterly Financial Information |
The following table contains selected quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.
|
|
Three Months Ended |
|
|
|
March 31,
2020 |
|
|
June 30,
2020 |
|
|
September 30,
2020 |
|
|
December 31,
2020 |
|
Revenue |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
4,069 |
|
|
|
2,488 |
|
|
|
2,684 |
|
|
|
1,925 |
|
General and administrative |
|
|
2,807 |
|
|
|
1,912 |
|
|
|
2,344 |
|
|
|
2,267 |
|
Total operating expenses |
|
|
6,876 |
|
|
|
4,400 |
|
|
|
5,028 |
|
|
|
4,192 |
|
Loss from operations |
|
|
(6,876 |
) |
|
|
(4,400 |
) |
|
|
(5,028 |
) |
|
|
(4,192 |
) |
Other income (expense), net |
|
|
62 |
|
|
|
10 |
|
|
|
5 |
|
|
|
(738 |
) |
Net loss |
|
|
(6,814 |
) |
|
|
(4,390 |
) |
|
|
(5,023 |
) |
|
|
(4,930 |
) |
Net loss per share—basic and diluted |
|
$ |
(0.24 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.13 |
) |
|
$ |
(0.12 |
) |
Weighted average common shares outstanding—
basic and diluted |
|
|
27,810,358 |
|
|
|
31,221,139 |
|
|
|
39,321,177 |
|
|
|
40,997,759 |
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(6,814 |
) |
|
$ |
(4,390 |
) |
|
$ |
(5,023 |
) |
|
$ |
(4,930 |
) |
Other comprehensive gain (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss) on investments, net of tax of $0 |
|
|
(8 |
) |
|
|
(1 |
) |
|
|
1 |
|
|
|
(1 |
) |
Total other comprehensive gain (loss) |
|
|
(8 |
) |
|
|
(1 |
) |
|
|
1 |
|
|
|
(1 |
) |
Total comprehensive loss |
|
$ |
(6,822 |
) |
|
$ |
(4,391 |
) |
|
$ |
(5,022 |
) |
|
$ |
(4,931 |
) |
|
|
Three Months Ended |
|
|
|
March 31,
2019 |
|
|
June 30,
2019 |
|
|
September 30,
2019 |
|
|
December 31,
2019 |
|
Revenue |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
4,174 |
|
|
|
4,305 |
|
|
|
4,475 |
|
|
|
4,709 |
|
General and administrative |
|
|
3,139 |
|
|
|
3,075 |
|
|
|
3,440 |
|
|
|
2,639 |
|
Total operating expenses |
|
|
7,313 |
|
|
|
7,380 |
|
|
|
7,915 |
|
|
|
7,348 |
|
Loss from operations |
|
|
(7,313 |
) |
|
|
(7,380 |
) |
|
|
(7,915 |
) |
|
|
(7,348 |
) |
Other income (expense), net |
|
|
101 |
|
|
|
208 |
|
|
|
166 |
|
|
|
112 |
|
Net loss |
|
|
(7,212 |
) |
|
|
(7,172 |
) |
|
|
(7,749 |
) |
|
|
(7,236 |
) |
Net loss per share attributable to common stockholders—basic and diluted |
|
$ |
(0.49 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.28 |
) |
|
$ |
(0.26 |
) |
Weighted average common shares outstanding—basic
and diluted |
|
|
14,816,253 |
|
|
|
27,526,065 |
|
|
|
27,810,358 |
|
|
|
27,810,358 |
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(7,212 |
) |
|
$ |
(7,172 |
) |
|
$ |
(7,749 |
) |
|
$ |
(7,236 |
) |
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized loss on investments, net of tax of $0 |
|
|
5 |
|
|
|
24 |
|
|
|
(7 |
) |
|
|
(10 |
) |
Total other comprehensive loss |
|
|
5 |
|
|
|
24 |
|
|
|
(7 |
) |
|
|
(10 |
) |
Total comprehensive loss |
|
$ |
(7,207 |
) |
|
$ |
(7,148 |
) |
|
$ |
(7,756 |
) |
|
$ |
(7,246 |
) |
|